Search results for "Virus Activation"

showing 10 items of 34 documents

Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.

2018

AbstractMonitoring the human virome has been recently suggested as a promising and novel area of research for identifying new biomarkers which would help physicians in the management of transplant patients. Imbalance of the immune system in transplant recipients has a significant impact on replication of Torquetenovirus (TTV), the most representative and abundant virus of human virome. TTV kinetic was studied by real-time PCR in 280 liver or kidney transplant recipients who underwent different drug regimens to maintain immunosuppression. During one-year post-transplant follow-up, TTV viremia fluctuated irrespective of transplanted organ type but consistent with the immunosuppression regimen…

0301 basic medicineMaleTime Factorsmedicine.medical_treatmentlcsh:MedicineCytomegalovirusVIROMEPostoperative ComplicationsANELLOVIRUSESlcsh:ScienceKidney transplantationTT VIRUSLUNG TRANSPLANTATIONDNA VIRUSAged 80 and overMultidisciplinaryIMMUNOSUPPRESSIONCMVvirus diseasesImmunosuppressionMiddle AgedViral LoadPrognosissurgical procedures operativeNEXT-GENERATIONCytomegalovirus InfectionsFemaleTORQUE TENO VIRUS; STEM-CELL TRANSPLANTATION; TT VIRUS; LUNG TRANSPLANTATION; NEXT-GENERATION; DNA VIRUS; IMMUNOSUPPRESSION; ANELLOVIRUSES; VIROME; HEPATITISViral loadAdult030106 microbiologyCongenital cytomegalovirus infectionTTVViremiaArticle03 medical and health sciencesHEPATITISYoung AdultmedicineHumansHuman viromeViremiaAgedImmunosuppression TherapyTorque teno virusbusiness.industrylcsh:RTTV; CMV; Transplant patientsSTEM-CELL TRANSPLANTATIONmedicine.diseaseKidney TransplantationTransplant RecipientsTransplantationRegimen030104 developmental biologyImmunologyTransplant patientslcsh:QVirus ActivationbusinessScientific reports
researchProduct

Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner

2007

Gammaherpesviruses are important pathogens whose lifelong survival in the host depends critically on their capacity to establish and reactivate from latency, processes regulated by both viral genes and the host immune response. Previous work has demonstrated that gamma interferon (IFN-gamma) is a key regulator of chronic infection with murine gammaherpesvirus 68 (gammaHV68), a virus that establishes latent infection in B lymphocytes, macrophages, and dendritic cells. In mice deficient in IFN-gamma or the IFN-gamma receptor, gammaHV68 gene expression is altered during chronic infection, and peritoneal cells explanted from these mice reactivate more efficiently ex vivo than cells derived from…

1109 Insect Sciencemedicine.medical_treatmentImmunologyCellSpleen610 Medicine & healthBiology10263 Institute of Experimental ImmunologyMicrobiologyInterferon-gammaGammaherpesvirinaeImmune systemVirologyVirus latencymedicineAnimalsHumansInterferon gammaDiphtheria toxinB-Lymphocytes2403 ImmunologyMacrophages2404 MicrobiologyHerpesviridae Infectionsmedicine.diseaseVirus LatencyCell biologyChronic infectionCytokinemedicine.anatomical_structureInsect ScienceImmunology2406 VirologyPathogenesis and Immunity570 Life sciences; biologyVirus Activationmedicine.drug
researchProduct

Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection

2021

Reactivation of latent cytomegalovirus (CMV) endangers the therapeutic success of hematopoietic cell transplantation (HCT) in tumor patients due to cytopathogenic virus spread that leads to organ manifestations of CMV disease, to interstitial pneumonia in particular. In cases of virus variants that are refractory to standard antiviral pharmacotherapy, immunotherapy by adoptive cell transfer (ACT) of virus-specific CD8+ T cells is the last resort to bridge the “protection gap” between hematoablative conditioning for HCT and endogenous reconstitution of antiviral immunity. We have used the well-established mouse model of CD8+ T-cell immunotherapy by ACT in a setting of experimental HCT and mu…

Adoptive cell transfermedicine.medical_treatmentImmunologyCytomegalovirusCD8-Positive T-LymphocytesLymphocyte ActivationCD8+ T cellsVirusCytomegalovirus VaccinesImmunocompromised HostAntigenvaccineMHC class ImedicineImmunology and AllergyCytotoxic T cellAnimalsCells Culturedadoptive cell transferCell ProliferationOriginal ResearchHCMV dense bodiesbiologybusiness.industryVaccinationHematopoietic Stem Cell TransplantationImmunotherapyRC581-607VirologyAdoptive TransferTransplantationMice Inbred C57BLantiviral protectionT cell primingDisease Models AnimalT cell receptor transgenic cellsCytomegalovirus InfectionsHost-Pathogen Interactionsbiology.proteinFemaleVirus Activationsubviral particlesImmunologic diseases. AllergybusinessCD8Frontiers in Immunology
researchProduct

Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopo…

2011

Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8(+) and CD4(+) T cell responses at days +30, +60 and +90 after transplantation in 133 patients, and established cutoff cell levels protecting from CMV DNAemia within the first 120 days after transplantation. No patients showing IFN-γ CD8(+) or IFN-γ CD4(+) T-cell counts1.0 and1.2 cells/μL, respectively, developed a subsequent episode of CMV DNAemia. Initial or recurrent episodes of CMV DNAemia occurred in the face of IFN-γ T-cell levels below defin…

AdultCD4-Positive T-LymphocytesMaleAdolescentGlobulinT cellCytomegalovirusCD8-Positive T-LymphocytesImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammamedicineHumansTransplantation HomologousAgedTransplantationCd4 t cellbiologyUmbilical Cord Blood Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyCmv dnaemiaMiddle AgedPhosphoproteinsTransplantationHaematopoiesismedicine.anatomical_structureCytomegalovirus InfectionsDNA ViralImmunologybiology.proteinFemaleVirus ActivationbusinessCD8Bone Marrow Transplantation
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation

2010

Human herpesvirus-6 (HHV-6) may enhance cytomegalovirus (CMV) replication in allogeneic stem cell transplant (allo-SCT) recipients either through direct or indirect mechanisms. Definitive evidence supporting this hypothesis are lacking. We investigated the effect of HHV-6 replication on active CMV infection in 68 allo-SCT recipients. Analysis of plasma HHV-6 and CMV DNAemia was performed by real-time PCR. Enumeration of pp65 and IE-1 CMV-specific IFNgamma CD8(+) and CD4(+)T cells was performed by intracellular cytokine staining. HHV-6 DNAemia occurred in 39.8% of patients, and was significantly associated with subsequent CMV DNAemia in univariate (P=.01), but not in multivariate analysis (P…

AdultMaleAdolescentInteractionHerpesvirus 6 Humanmedicine.medical_treatmentvirusesCongenital cytomegalovirus infectionRoseolovirus InfectionsVirus ReplicationYoung AdultHomologous chromosomemedicineHumansTransplantation HomologousCMV replicationAgedImmunosuppression TherapyTransplantationHuman herpesvirus 6 (HHV-6)biologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesImmunosuppressionHematologyMiddle Agedmedicine.diseasebiology.organism_classificationAllo-SCT recipientVirologyCMV immune responseTransplantationViral replicationCytomegalovirus InfectionsDNA ViralImmunologyFemaleVirus ActivationHuman herpesvirus 6Stem cellCytomegalovirus (CMV)businessCD8Biology of Blood and Marrow Transplantation
researchProduct

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

2013

OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…

AdultMaleHepatitis B virusTime Factorsoccult HBV-DNAAntiviral AgentsPolymerase Chain ReactionRisk AssessmentRisk FactorsRheumatic Diseasesoccult HBV-DNA rheumatic diseases anti-TNFHumansProspective Studiesrheumatic diseaseAcademic Medical CentersHepatitis B Surface AntigensTumor Necrosis Factor-alphavirus diseasesanti-TNFMiddle AgedHepatitis Bdigestive system diseasesTreatment OutcomeItalyLamivudineAntirheumatic AgentsDNA ViralFemaleVirus ActivationBiomarkers
researchProduct

Stochastic Episodes of Latent Cytomegalovirus Transcription Drive CD8 T-Cell “Memory Inflation” and Avoid Immune Evasion

2021

Acute infection with murine cytomegalovirus (mCMV) is controlled by CD8+ T cells and develops into a state of latent infection, referred to as latency, which is defined by lifelong maintenance of viral genomes but absence of infectious virus in latently infected cell types. Latency is associated with an increase in numbers of viral epitope-specific CD8+ T cells over time, a phenomenon known as “memory inflation” (MI). The “inflationary” subset of CD8+ T cells has been phenotyped as KLRG1+CD62L- effector-memory T cells (iTEM). It is agreed upon that proliferation of iTEM requires repeated episodes of antigen presentation, which implies that antigen-encoding viral genes must be transcribed du…

CD4-Positive T-LymphocytesGene Expression Regulation Viral0301 basic medicineMuromegaloviruslatent infectionTime FactorsTranscription Geneticeffector memory CD8+ T cellsAntigen presentationImmunologyBiologyVirusImmediate-Early Proteins03 medical and health sciences0302 clinical medicineImmune systemImmunityAnimalsCytotoxic T cellImmunology and AllergyLatency (engineering)Antigens ViralLungGenememory inflationlatencyOriginal Researchimmune evasionMice Inbred BALB CStochastic ProcessesModels ImmunologicalHerpesviridae InfectionsRC581-607VirologyVirus LatencyDisease Models Animalvirus reactivationantigen presentationPhenotype030104 developmental biologyHost-Pathogen Interactionsgene expressionFemaleVirus ActivationImmunologic diseases. AllergyImmunologic MemoryCD8030215 immunologyFrontiers in Immunology
researchProduct